DK1740217T3 - Meningokok-konjugat-vaccination - Google Patents

Meningokok-konjugat-vaccination

Info

Publication number
DK1740217T3
DK1740217T3 DK05738559.3T DK05738559T DK1740217T3 DK 1740217 T3 DK1740217 T3 DK 1740217T3 DK 05738559 T DK05738559 T DK 05738559T DK 1740217 T3 DK1740217 T3 DK 1740217T3
Authority
DK
Denmark
Prior art keywords
carrier protein
patient
diphtheria toxoid
meningococcal
conjugates
Prior art date
Application number
DK05738559.3T
Other languages
English (en)
Inventor
Cameron Marshall
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35057184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1740217(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0409750A external-priority patent/GB0409750D0/en
Priority claimed from GBGB0500787.7A external-priority patent/GB0500787D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1740217T3 publication Critical patent/DK1740217T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05738559.3T 2004-04-30 2005-04-29 Meningokok-konjugat-vaccination DK1740217T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0409750A GB0409750D0 (en) 2004-04-30 2004-04-30 Integration of meningococcal conjugate vaccination
GBGB0500787.7A GB0500787D0 (en) 2005-01-14 2005-01-14 Integration of meningococcal conjugate vaccination
PCT/GB2005/001653 WO2005105140A2 (en) 2004-04-30 2005-04-29 Meningococcal conjugate vaccination

Publications (1)

Publication Number Publication Date
DK1740217T3 true DK1740217T3 (da) 2011-09-26

Family

ID=35057184

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05738559.3T DK1740217T3 (da) 2004-04-30 2005-04-29 Meningokok-konjugat-vaccination

Country Status (15)

Country Link
US (2) US9402915B2 (da)
EP (2) EP2272531A3 (da)
JP (2) JP5718545B2 (da)
AT (1) ATE512670T1 (da)
AU (1) AU2005237289B2 (da)
BR (1) BRPI0510315A (da)
CY (1) CY1111814T1 (da)
DK (1) DK1740217T3 (da)
MX (1) MXPA06011994A (da)
NZ (1) NZ550533A (da)
PL (1) PL1740217T3 (da)
PT (1) PT1740217E (da)
RU (1) RU2379052C2 (da)
SI (1) SI1740217T1 (da)
WO (1) WO2005105140A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
ATE512670T1 (de) 2004-04-30 2011-07-15 Novartis Vaccines & Diagnostic Meningokokken-konjugat-impfung
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
PT2351578T (pt) 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
DK3017827T3 (da) 2005-12-22 2019-02-18 Glaxosmithkline Biologicals Sa Pneumokok-polysaccharidkonjugat-vaccine
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
PT2004225E (pt) 2006-03-22 2012-05-30 Novartis Ag Regimes para imunização com conjugados meningocócicos
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CN101265288B (zh) * 2007-03-13 2012-03-21 齐鲁制药有限公司 Crm197突变体的纯化方法
CN101314619B (zh) * 2007-06-01 2010-12-22 齐鲁制药有限公司 肿瘤治疗性疫苗ctp37crm197免疫原及其制备方法与应用
PL2167121T3 (pl) 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
PL3246044T3 (pl) 2010-08-23 2021-08-23 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
JP6048845B2 (ja) 2011-06-01 2016-12-21 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
CN104334187B (zh) 2012-03-09 2017-04-05 辉瑞公司 脑膜炎双球菌组合物及其方法
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP3620172A1 (en) * 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CN105492021B (zh) 2013-09-08 2018-12-04 辉瑞公司 脑膜炎奈瑟氏球菌组合物及其方法
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2018045286A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB323103A (en) 1928-12-07 1929-12-24 Fred Cunningham Firth Improvements relating to shaper mechanism for winding yarn on weft bobbins in spinning mules
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
DE69331495T2 (de) 1992-08-31 2002-10-31 Baxter Healthcare Sa Impfstoffe gegen neisseria meningitidis gruppe c
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
ATE400295T1 (de) 1995-06-07 2008-07-15 Glaxosmithkline Biolog Sa Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein
ES2325301T3 (es) 1995-06-23 2009-09-01 Glaxosmithkline Biologicals S.A. Composicion de vacuna que comprende un antigeno polisacarido conjugado, adsorbido sobre fosfato de aluminio.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
CA2283557A1 (en) 1997-03-10 1998-09-17 Heather L. Davis Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2201551T3 (es) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999040936A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
CN1296416A (zh) 1998-04-09 2001-05-23 史密丝克莱恩比彻姆生物有限公司 佐剂组合物
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO2000004136A1 (en) 1998-07-15 2000-01-27 Novozymes A/S Glucoamylase variants
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
JP2003519084A (ja) 1998-10-16 2003-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2000056360A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against antigens from bacteriae
WO2001021152A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
MXPA02003067A (es) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Uso de combinacion de ester sorbitano de polioxietileno y octoxinol como adjuvante y su uso en vacunas.
PT1248647E (pt) * 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
JP4870895B2 (ja) 2000-06-29 2012-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
US7262286B2 (en) 2000-09-26 2007-08-28 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
PT1355673E (pt) 2001-01-23 2012-08-31 Sanofi Pasteur Inc Vacina meningocócica multivalente preparada com um conjugado de polissacárido e proteína
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
WO2003024481A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
ES2318117T3 (es) 2002-03-26 2009-05-01 Novartis Vaccines And Diagnostics S.R.L. Sacaridos modificados que tienen una estabilidad mejorada en agua.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2485999C (en) 2002-05-14 2015-02-17 Chiron Srl Mucosal combination vaccines for bacterial meningitis
AU2003257003A1 (en) 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
GB0217909D0 (en) 2002-08-01 2002-09-11 Du Pont Chintzed stretch fabrics
PT2351579T (pt) 2002-10-11 2016-12-22 Novartis Vaccines And Diagnostics S R L Vacinas polipeptídicas para proteção ampla contra linhagens meningocócicas hipervirulentas
EP1587473A4 (en) 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
US20050002957A1 (en) * 2003-05-07 2005-01-06 Ryall Robert P. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
US20050002948A1 (en) * 2003-05-07 2005-01-06 Ryall Robert P. Method of enhanced immunogenicity to meningococcal vaccination
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
EP1644036A2 (en) 2003-06-23 2006-04-12 Sanofi Pasteur Inc. Immunization method against neisseria meningitidis serogroups a and c
CN100423774C (zh) * 2003-08-06 2008-10-08 美国政府健康及人类服务部 制备多糖-蛋白轭合物疫苗的方法
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
ATE512670T1 (de) 2004-04-30 2011-07-15 Novartis Vaccines & Diagnostic Meningokokken-konjugat-impfung
WO2007071786A2 (en) 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines

Also Published As

Publication number Publication date
CY1111814T1 (el) 2015-10-07
US10064932B2 (en) 2018-09-04
JP2013116915A (ja) 2013-06-13
EP1740217B1 (en) 2011-06-15
PL1740217T3 (pl) 2012-03-30
US9402915B2 (en) 2016-08-02
US20160303215A1 (en) 2016-10-20
EP1740217A2 (en) 2007-01-10
EP2272531A3 (en) 2011-04-13
AU2005237289A1 (en) 2005-11-10
EP2272531A2 (en) 2011-01-12
WO2005105140A3 (en) 2006-01-19
JP5718545B2 (ja) 2015-05-13
NZ550533A (en) 2010-02-26
WO2005105140A2 (en) 2005-11-10
JP2007535527A (ja) 2007-12-06
US20090060945A1 (en) 2009-03-05
SI1740217T1 (sl) 2011-10-28
RU2006142158A (ru) 2008-06-20
MXPA06011994A (es) 2007-01-25
PT1740217E (pt) 2011-08-02
AU2005237289B2 (en) 2011-08-04
ATE512670T1 (de) 2011-07-15
RU2379052C2 (ru) 2010-01-20
BRPI0510315A (pt) 2007-10-16

Similar Documents

Publication Publication Date Title
ATE512670T1 (de) Meningokokken-konjugat-impfung
DK1835939T3 (da) Meningokokkonjugatvaccination
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
NO20015073D0 (no) Vaksiner
MA25824A1 (fr) Compostion de vaccin polyvalente
MX2010004271A (es) Formulaciones de vacuna meningococica.
DK1725258T3 (da) Kombinationsvacciner med lav dosis Hib-konjugat
CR10123A (es) Vacuna.
EA200801344A1 (ru) Пневмококковая полисахаридная конъюгатная вакцина
DK2004225T3 (da) Programmer for vaccination med meningocockonjugater